 Data from phase 1b study using SBP-101 for patients with pancreatic cancer will be shown at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium on January 20- 22, 2022. Pancreatic cancer patients in cohort 2 given SBP-101 chemotherapies achieved ORR of 71; Cohort 4 patients achieved ORR of 48 but median overall survival has not yet been reached. 